Mobile vision care goes global
OptikosPrime just obliterated the primary barrier in digital optometry. The company announced today that it has successfully derived a complete eye prescription using only a standard smartphone camera. Developed under the internal platform name Argus, its vision tests bypass the need for traditional optometry hardware or specialized clinical personnel.
In short, OptikosPrime’s Argus provides a prescription based on a selfie.
The global eyewear market is projected to reach $192.74 billion in 2026, according to Fortune Business Insights. Despite this massive valuation, the industry remains tethered to physical locations for accurate prescriptions, or app/laptop solutions that require complex and multi-device setup. Current online leaders such as 1-800 Contacts and Lensabl offer online prescription renewals, but these typically require a valid prescription on file.
They confirm what you already know rather than discovering what you need.
Bridging the Gap Between Screening and Solution
Most existing digital eye care tools function as digital yardsticks. They measure visual acuity by asking users to identify letters on a screen. While these apps indicate whether a person has blurry vision, they ultimately lead nowhere. They cannot tell a patient which lens they actually need. This creates a massive operational bottleneck for retailers and humanitarian groups. They must still rely on heavy, expensive machinery to finalize a sale or a treatment.
Argus changes the physics of the problem. It moves beyond simple vision screening to provide the specific refraction data required for corrective lenses.
“If Argus provides a super fast, accurate, and high-quality refraction for online consumers, it will be a game-changer,” says Doron Kalinko, Co-founder of SmartBuyGlasses. “This is precisely what the industry needs.”
Market Dynamics and the Billion-Person Problem
The stakes are high in the humanitarian sector. The World Health Organization estimates that over 2.2 billion people worldwide live with vision impairment. For roughly 1 billion of them, the impairment is avoidable or unaddressed. Often, the obstacle is not the cost of the frames; it is the lack of a professional to advise them on which glasses to buy.
Access to clear vision should not depend on geography. “Innovations like Argus have the potential to transform how communities worldwide receive eye care,” Sumrana Yasmin, Deputy Technical Director for Eye Health at Sightsavers, said. “This breakthrough shows what is possible when innovation is guided by equity and a commitment to reaching the hardest to reach communities.”
Engineered for the Chaos of the Real World
Clinical equipment works because the environment is controlled. In the wild, lighting is inconsistent, users have shaky hands, and reflections bounce off the cornea. OptikosPrime spent years wrestling these variables into submission. The tech is designed to work in under sixty seconds on a standard mobile device. This makes it viable for high-volume retail or remote village outreach, where a $20,000 phoropter or a $5,000 autorefractor is not feasible.
“Speed and simplicity are non-negotiable,” Ståle Fredlund Husby, Co-founder at OptikosPrime, said. “If a solution needs several devices, careful setup, or multiple minutes per person, it simply does not work in rural outreach or online retail environments.”
Technical Milestones and Future Growth
OptikosPrime is the first entity to publicly confirm reaching this technological milestone. While other companies have experimented with hardware attachments or complex multi-step processes, OptikosPrime is the first to claim a full prescription from a simple photo.
“Building state-of-the-art technology that moves measurements of physical phenomena from well-controlled environments and into the wild is a significant research and development challenge,” Anders Kofod-Petersen, Co-founder and CEO at OptikosPrime, said. “The intellectual and technical effort to achieve this has been significant: it was a classic two steps forward and one step back process relying on rigorous science.”
The company is currently preparing for its next funding round. This capital will accelerate data acquisition, clinical validation, and the regulatory navigation required to deploy Argus globally. In the interim, OptikosPrime continues to scale its first commercial product, VisionCheck, which provides mobile vision screening to the current market.
